# Bronchiectasis Alpha-1 Augmentation Trial- Modulating Airway Neutrophil Function

> **NCT05582798** · PHASE4 · COMPLETED · sponsor: **University of Dundee** · enrollment: 20 (actual)

## Conditions studied

- Bronchiectasis Adult

## Interventions

- **DRUG:** Alpha 1-Proteinase Inhibitor 180mg/kg
- **DRUG:** Alpha 1-Proteinase Inhibitor 120mg/kg
- **DRUG:** Sodium chloride

## Key facts

- **NCT ID:** NCT05582798
- **Lead sponsor:** University of Dundee
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-11-01
- **Primary completion:** 2024-08-12
- **Final completion:** 2024-08-12
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2024-09-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05582798

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05582798, "Bronchiectasis Alpha-1 Augmentation Trial- Modulating Airway Neutrophil Function". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT05582798. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*